Ellis expects the trial to reopen for enrollment after a 60-day review. Genentech will still follow through with a U.S. trial of Avastin plus Folfox, compared with Folfox alone, in a group of post-surgery later-stage colorectal cancer patients. Unlike the Avant study, this trial doesn't include a Xelox arm.
"This decision further underscores the belief that the safety concerns seen in Avant are limited to Xelox plus Avastin," according to Rodman & Renshaw's Mike King. Avastin is already approved as a first-line treatment of metastatic colorectal cancer. The suspended study was reviewing the drug as a so-called adjuvant therapy designed to prevent the cancer from recurring. Genentech's shares fell $2.04, or 2.4%, to $81.48 Monday.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,217.12 | 1,089.96 | 2,145.99 | 34.95 |
Oil *
76.53
|
|
DOWN
9.82
|
DOWN
3.11
|
DOWN
8.07
|
UP
0.09
|
10 Yr
3.50%
SPDR Gold
107.90
|
|
-0.10%
|
-0.28%
|
-0.37%
|
+0.26%
|
Data delayed 20 minutes |














